| Target Price | £4.23 |
| Price | £2.06 |
| Potential |
105.49%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Videndum 2027 .
The average Videndum target price is £4.23.
This is
105.49%
register free of charge
£4.36
111.53%
register free of charge
£4.19
103.47%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Videndum to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Videndum stock has an average upside potential 2027 of
105.49%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million £ | 228.90 | 237.62 |
| 18.45% | 3.81% | |
| EBITDA Margin | 5.07% | 11.53% |
| 196.77% | 127.52% | |
| Net Margin | -29.97% | -0.77% |
| 42.77% | 97.43% |
4 Analysts have issued a sales forecast Videndum 2026 . The average Videndum sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Videndum EBITDA forecast 2026. The average Videndum EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Videndum Analysts have issued a net profit forecast 2026. The average Videndum net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share £ | -132.41 | -0.05 |
| 57.57% | 99.96% | |
| P/E | negative | |
| EV/Sales | 0.51 |
4 Analysts have issued a Videndum forecast for earnings per share. The average Videndum EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


